ARTICLE | Company News
Myriad Genetics, AstraZeneca deal
April 20, 2015 7:00 AM UTC
AstraZeneca and Myriad expanded a 2013 deal and will use Myriad’s BRACAnalysis CDx test to identify metastatic pancreatic cancer patients likely to respond to the pharma’s Lynparza olaparib. Under t...